EXCLUSIVE: Medtronic’s strategy guru on the $43B Covidien buy

EXCLUSIVE: Medtronic's strategy guru on the $43B Covidien buy

The pending $43 billion merger of Medtronic (NYSE:MDT) and Covidien (NYSE:COV) triggered speculation that the combined medical device giant would scale back on its strategic investment program. After all, there’s a lot to digest in integrating a buyout of that size, the thinking goes, and the move likely takes 2 prolific acquirers off the board.

But the opposite is true, according to Geoff Martha, the Medtronic strategy & business development executive charged with managing the integration of Covidien.

In a June 24 interview at Medtronic’s headquarters in Fridley, Minn., (the same day Medtronic tapped him as its chief integration officer), Martha told MassDevice.com that the effect of the Covidien deal on Medtronic’s balance sheet – a massive infusion of some $12 billion to $14 billion in cash – frees the company to accelerate its acquisition program.

"It changes our outlook on minority investments and acquisitions, because this add have more cash, more balance sheet flexibility in the U.S.," Martha told us. "Where this helps is particularly in those companies that have gotten to a decent valuation in segments we want to enter. They’re still earlier-stage companies, maybe no revenue or just revenue in developed markets or just U.S., but they still have a big valuation because they’ve de-risked some sort of breakthrough therapy. This helps us with those, because we found ourselves making trade-offs in that area, where we had the organizational capability to do many of them but the balance sheet flexibility to do a few of them."

The Covidien deal includes a commitment to spending $10 billion over a decade on "technology investments" in the U.S. "in areas such as early stage venture capital investments, acquisitions and R&D," Medtronic said when it announced the merger June 15. Martha said that $10 billion "is incremental over what we would forecast Covidien and Medtronic to do on their own."

"Then in the minority investment portfolio, worst case it’s business as usual, but more likely, I think we’ll accelerate that as well," he said. "It all comes back to having the balance sheet flexibility. We are very comfortable at Medtronic in market development. You’ve got the technology piece, you’ve got the clinical piece and the distribution to scale it.

MassDevice.com news

Martha

"I would argue that both Medtronic and Covidien are very strong technology companies, but I think where Medtronic has significantly more scale is in the clinical side," Martha explained. "If you take our clinical comfort and our confidence that we can invest in a technology company and then design a clinical trial and work with the [key opinion leaders] to make it standard of care, I think it should increase the amount of overall minority investments that are being made."

To outsiders the deal seemed to come together with lightning speed, following a dinner meeting in April between Medtronic CEO Omar Ishrak and Covidien chief executive Joe Almeida. But Martha, a former Ishrak lieutenant from GE Healthcare hired in August 2011, told us that Medtronic had been looking at Covidien for some time before then.

"It definitely wasn’t something that came together over 3 months. It was something we’ve been thinking about for a while, but when they met at that dinner they got into a pretty deep conversation and realized that there’s an opportunity. Then from there, it did accelerate. You can’t have these type of conversations drag out. That April dinner was when it really accelerated up to signing," he said. "We’re always looking. We’ve looked at Covidien and others over the years since I’ve been here. From the day I got here, we’ve been looking at different opportunities."

Asked about the merger’s implications for the rest of the medtech world, Martha said that companies must now decide whether to buy into the view that developing a ground-breaking technology is no longer enough to ensure success.

"I think you’ve got to pick. Medtech grew up as a very technology-focused, product-focused industry, and that worked. If you had a product that had the clinical efficacy, it sold. It sold and physicians would pick it for the clinical reasons and it sold. Now, the bar’s gotten higher to economic value, added on to clinical value. Not every place, though. Getting economic value from just a product sometimes is difficult and you need to wrap that with solutions and services. In some cases, that takes a broader set of products," he said. "If you buy into that, then I would think you’d be looking to attach yourself to somebody that can do that. If you don’t believe that, and you think that this whole accountable care organization stuff is just another fad, then I think being more focused on technology is fine. So I think you’re going to have people either not making a decision and being confused or some proactively saying, ‘I’m going to be a very focused technology company and I’ll get bought by somebody bigger.’ If you’re a small- or mid-cap and you have a great product portfolio that is really differentiated, there’s room for that. The mid-caps that buy into our thinking are probably going to look for partnerships."

RSS From Medical Design & Outsourcing

  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]
  • TSO3 begins shipment of STERIZONE VP4 Sterilizers to U.S.
    TSO3, a developer in sterilization technology for medical devices in healthcare settings, announced that the company has received purchase orders for multiple devices from the U.S. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and TSO3. “Finally,” said R.M. Rumble, president and CEO of TSO3. “Our Vision is […]
  • Turkish medical company is seeking reseller and OEM partners in the U.S.
    UZUMCU Medical Equipment, one of Turkey’s first and largest manufacturers of medical devices, is seeking reseller and OEM partners in the U.S. The company has an array of FDA-certified OR tables, surgical lights, surgical suction units, electro devices and other medical equipment. “We want to bring our experience with distributors throughout Europe and the Middle […]
  • QImaging introduces new CCD cameras for microscopy with modern software to streamline image capture
    QImaging, a manufacturer of scientific cameras for life science and OEM applications, introduces a new series of Retiga CCD cameras, accompanied by QImaging’s new acquisition software to deliver high-performance tools for microscopy and imaging to researchers at an affordable price. The new QImaging Retiga R1, Retiga R3 and Retiga R6 cameras offer valuable technical features […]
  • Sigma-Aldrich announces a new certification to aid IVD customers
    Sigma-Aldrich, a life science and high technology company, announced the company has received ISO 13485 certification for expanded quality assurance capabilities at its Dekalb and Barton facilities located in St. Louis. The certification extends Sigma-Aldrich’s ability to manufacture and offer critical raw materials, such as enzymes, proteins and antibodies used in diagnostic assays, and supplies in vitro […]
  • Prescribing the right power supply: Important considerations for using batteries to power medical devices
    Sol Jacobs, VP and General Manager, Tadiran Batteries Medical technology is advancing rapidly, requiring increasingly sophisticated power management solutions, especially when then the device needs to be self-powered. Battery-powered medical devices encompass a wide range of applications, including surgical drills, power tools, automatic external defibrillators (AEDs), infusion pumps, bone growth stimulators and other wearable devices, […]
  • Qosina announces the launch of its e-commerce website
    Qosina is pleased to announce the launch of its e-commerce website, making it easier to purchase thousands of medical device components from stock inventory. Visitors coming to the new Qosina.com will discover a new look and feel and improvements with every click including: · Easy navigation: A new category structure that mirrors the print catalog […]
  • Athermal laser machining for medical implants is the topic of Norman Noble’s latest whitepaper
    Thermal lasers have achieved extraordinary results in microprecision manufacturing of medical implants and devices the past 20 years. Devices we take for granted today, such as vascular stents, could not be produced without the technology; however, there are still significant limitations on what medical implant and device manufactures can produce using thermal lasers. One major issue […]
  • Sealevel announces the SeaISO family of USB isolators
    Sealevel announces the SeaISO family of USB isolators with 4 kV of medical-grade optical isolation between the host computer and connected USB equipment. SeaISO USB isolators are UL Recognized, in accordance with EN60601-1 3rd Edition, and protect both the power and data lines of connected USB devices from harmful ground loops, damaging transients and surges […]
  • The 21st Century Cures Discussion document recently released to the public
    It has been reported that among the 10,000 known diseases, 7,000 of which are considered rare, there are treatments for only 500. According to Dr. Francis Collins, Director of the National Institutes of Health (NIH), it now takes “around 14 years and $2 billion or more” to develop a new drug and “more than 95% […]

Leave a Reply